retatrutide nejm 2023 obesity trial ly3437943 This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist for — A Phase 2 https://t.co/jNL1GNnHPT #Endocrinology Retatrutide: Phase 3 Results (Up

These medications potently and selectively inhibit the enzymatic activity of DPP-4, enhancing the effectiveness of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which are the primary incretins (endogenous glucoregulatory peptides, [39,40,41])

Saxenda also reduces the risk of cardiovascular events like heart attacks and strokes

The top layers of your skin will be inflamed after microneedling

Common errors include injecting repeatedly in the same spot, incorrect depth, reusing needles, and not holding the pen in place long enough after injection

Automated speech analysis in bipolar disorder: the CALIBER study protocol and preliminary results

Marijuana and Public Health Publications, accessed 8 February 2023 at Kinney GL, Akturk HK, Taylor DD, Foster NC, Shah VN